Ad26.COV2.S的安全性与反应原性及免疫原性:日本1期随机双盲安慰剂对照COVID-19疫苗试验结果
本研究在日本成人中评估Ad26.COV2.S同源加强方案的安全性、反应原性和免疫原性。多中心1期试验将两个年龄队列各125人按2:2:1随机分配接受5×10^10 vp、1×10^11 vp或安慰剂,56天后同源加强。200人接种疫苗、50人接受安慰剂;接种后中和抗体和结合抗体水平升高,加强后14天中和抗体GMT在队列1接近峰值、队列2达峰,安全性可接受。
要点
- 最常见征集性局部不良事件为接种部位疼痛,最常见征集性全身不良事件为疲乏、肌痛和头痛。
- 队列1加强后14天中和抗体GMT:5×10^10 vp组1049,1×10^11 vp组1470;队列2分别为504和651。
- 两队列结合抗体水平均在Day 71达峰,Day 85轻微下降。
核心结论
- 单剂及同源Ad26.COV2.S加强针在日本成人中增加抗体应答,安全性特征可接受。
研究设计与样本
- 多中心、安慰剂对照1期试验,队列1为20-55岁成人N=125,队列2为≥65岁成人N=125,按2:2:1随机接受Ad26.COV2.S 5×10^10 vp、1×10^11 vp或安慰剂,56天后同源加强。
- 共200人接受Ad26.COV2.S,50人接受安慰剂。
主要发现
- 最常见征集性局部不良事件为接种部位疼痛,最常见征集性全身不良事件为疲乏、肌痛和头痛。
- 初次接种后两队列中和抗体及结合抗体水平至Day 57(初免后)升高。
- 加强后14天(Day 71)中和抗体GMT在队列1接近峰值(5×10^10 vp组GMT=1049;1×10^11 vp组GMT=1470),在队列2达峰(504;651)。
- Day 85时队列2中和抗体GMT轻微下降;两队列结合抗体水平均在Day 71达峰,Day 85轻微下降。
关键数值与推荐
- 队列1加强后14天中和抗体GMT:5×10^10 vp组1049,1×10^11 vp组1470。
- 队列2加强后14天中和抗体GMT:5×10^10 vp组504,1×10^11 vp组651。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated safety, reactogenicity, and immunogenicity of a 2-month homologous booster regimen of Ad26.COV2.S in Japanese adults. METHODS: In this multicenter, placebo-controlled, Phase 1 trial, adults (Cohort 1, aged 20-55 years, N = 125; Cohort 2, aged ≥ 65 years, N = 125) were randomized 2:2:1 to receive Ad26.COV2.S 5 × 1010 viral particles (vp), Ad26.COV2.S 1 × 1011 vp, or placebo, followed by a homologous booster 56 days later. Safety, reactogenicity, and immunogenicity were assessed. RESULTS: Two hundred participants received Ad26.COV2.S and 50 received placebo. The most frequent solicited local adverse event (AE) was vaccination-site pain, and the most frequent solicited systemic AEs were fatigue, myalgia, and headache. After primary vaccination, neutralizing and binding antibody levels increased through Day 57 (post-prime) in both cohorts. Fourteen days after boosting (Day 71), neutralizing antibody geometric mean titers (GMTs) had almost reached their peak value in Cohort 1 (5 × 1010 vp: GMT = 1049; 1 × 1011 vp: GMT = 1470) and peaked in Cohort 2 (504; 651); at Day 85, GMTs had declined minimally in Cohort 2. For both cohorts, binding antibody levels peaked at Day 71 with minimal decline at Day 85. CONCLUSION: A single dose and homologous Ad26.COV2.S booster increased antibody responses with an acceptable safety profile in Japanese adults (ClinicalTrials.gov Identifier: NCT04509947).
引用
- Tsuchiya Y, Tamura H, Fujii K, et al. Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan. Vaccine. 2023. PMID: 36732164. doi:10.1016/j.vaccine.2023.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。